New variant?
This really makes the fact much more amazing that China will help Egypt to produce 1.2 billion doses of Sinovac vaccines a year.Inactivated vaccines are a lot more difficult to make than mRNA vaccines, because it requires mass culture and inactivation of live viruses, which require extremely rigorous safety levels. I've read that only China has the capability to produce inactivated vaccines on such a large scale.
Egypt said Wednesday it plans to manufacture one billion doses a year of China's Sinovac vaccine, claiming it would become the Middle East and Africa's "biggest vaccine producer".
Under the deal with the Chinese pharmaceutical company, a factory in Cairo will produce more than 200 million doses per year to cover "national needs", Health Minister Hala Zayed told a press conference.
A second factory will produce three million doses per day, "or around a billion a year", with a view to exporting the vaccine for Covid-19 and responding to demand in Africa, Zayed added.
The move would make Egypt "the biggest vaccine producer in the Middle East and Africa", an official statement said.
Heba Wali, the doctor in charge of the project, said the Egyptian drug authority had given its go-ahead and that "one million doses have already been distributed in Egypt".
Chinese experts had previously traveled to Egypt to inspect equipment and materials for producing the Sinovac vaccine at factories belonging to state firm Vacsera.
Egypt, with a population of over 100 million, has officially recorded more than 288,000 Covid-19 cases, including over 16,700 deaths.
Some 7.5 million Egyptians have had at least one vaccine.
AFP
It could be. If the report that came out before is true, then 2/3 of Indians already infected with Delta. In addition, vaccination rate has gone up substantially. So it would take a new variant to bring another wave in India.New variant?
Just to recap. There are at least three (probably more) Chinese vaccine candidates in phase III trials. Walvax's mRNA vaccine, unlike the other two, has yet to publish its phase I and phase II results.
Clover's candidate and Livzon's candidate are similar in their neutralizing antibodies count but Clover uses American adjuvants so it's unlikely to use domestic use in China, although it has already secured a 400+ million order from GAVI. I'm not sure about Walvax's supply chain but I think they'll want to use as little as US components as possible.
Livzon is very interesting in that it uses traditional adjuvant but produces similar level of neutralizing antibodies as Clover's. Protein subunit vaccines are probably the easiest ones to mass produce and if Livzon's vaccine is successful China will have a winner.
I didnt realize there was phase II results for both Livzon and SCB-2019, can you provide a link?
Did you read about the desperate things the DPP regime is doing?Mainland vaccines in Taiwan.